A randomized controlled study of 33 non-dialysis CKD patients showed that serum hepcidin levels were decreased after 2 weeks of treatment with ESA, suggesting that the ESA-associated change in hepcidin level predicted an early and long-term bone marrow response21. This evidence concerns the gene HAMP and chronic kidney disease.